Online inquiry

IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13286MR)

This product GTTS-WQ13286MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PTK7 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001270398.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5754
UniProt ID Q13308
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13286MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5228MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ12687MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ10236MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ7647MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GEN-1029
GTTS-WQ15088MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ9015MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ1942MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ14477MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RO-7105705
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW